Aeglea BioTherapeutics Inc
AGLE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.02B
Close$
$12.29
2.4% upside
Current Fair Value
2.4% upsideUndervalued by 2.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.02 Billion |
|---|---|
| Enterprise Value | $855.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.98 |
| Beta | 2.57 |
| Outstanding Shares | 84,729,435 |
Return
| Return on Equity | -16.25% |
|---|---|
| Return on Assets | -15.25% |
| Return on Invested Capital | -18.14% |
Valuation & Multiples
| P/E Ratio | -43.94 |
|---|---|
| PEG | 3120.84 |
| Price to Sales | - |
| Price to Book Ratio | 1.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.56 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data